Learn About Granulomatosis with Polyangiitis

What is the definition of Granulomatosis with Polyangiitis?

Granulomatosis with polyangiitis (GPA) is a rare disorder in which blood vessels become inflamed. This leads to damage in major organs of the body. It was formerly known as Wegener's granulomatosis.

Save information for later
Sign Up
What are the alternative names for Granulomatosis with Polyangiitis?

Formerly: Wegener's granulomatosis

What are the causes of Granulomatosis with Polyangiitis?

GPA mainly causes inflammation of blood vessels in the lungs, kidneys, nose, sinuses, and ears. This is called vasculitis or angiitis. Other areas may also be affected in some cases. The disease can be fatal and prompt treatment is important.

In most cases, the exact cause is not known, but it is an autoimmune disorder. Rarely, vasculitis with positive antineutrophil cytoplasmic antibodies (ANCA) has been caused by several drugs including cocaine cut with levamisole, hydralazine, propylthiouracil, and minocycline.

GPA is most common in middle-aged adults of northern European descent. It is rare in children.

What are the symptoms of Granulomatosis with Polyangiitis?

Frequent sinusitis and bloody noses are the most common symptoms. Other early symptoms include a fever that has no clear cause, night sweats, fatigue, and a general ill feeling (malaise).

Other common symptoms may include:

  • Chronic ear infections
  • Pain, and sores around the opening of the nose
  • Cough with or without blood in the sputum
  • Chest pain and shortness of breath as the disease progresses
  • Loss of appetite and weight loss
  • Skin changes such as bruises and ulcers of the skin
  • Kidney problems
  • Bloody urine
  • Eye problems ranging from mild conjunctivitis to severe swelling of the eye

Less common symptoms include:

  • Joint pain
  • Weakness
  • Abdominal pain
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Granulomatosis with Polyangiitis?

Because of the potentially serious nature of GPA, you may be hospitalized. Once the diagnosis is made, you will probably be treated with high doses of glucocorticoids (such as prednisone). These are given through the vein for 3 to 5 days at the beginning of treatment. Prednisone is given along with other medicines that slow down the immune response.

For milder disease other medicines that slow down the immune response such as methotrexate or azathioprine may be used.

Common medicines for vasculitis include:

  • Rituximab (Rituxan)
  • Cyclophosphamide (Cytoxan)
  • Methotrexate
  • Azathioprine (Imuran)
  • Mycophenolate (Cellcept or Myfortic)

These medicines are effective in severe disease, but they may cause serious side effects. Most people with GPA are treated with ongoing medicines to prevent relapse for at least 12 to 24 months. Talk to your health care provider about your treatment plan.

Other medicines used for GPA include:

  • Medicines to prevent bone loss caused by prednisone
  • Folic acid or folinic acid, if you are taking methotrexate
  • Antibiotics to prevent lung infections
Who are the top Granulomatosis with Polyangiitis Local Doctors?
Elite
Highly rated in
21
conditions
Rheumatology

Penn Medicine

Perelman Center For Advanced Medicine

3400 Civic Center Blvd, 
Philadelphia, PA 

Peter Merkel is a Rheumatologist in Philadelphia, Pennsylvania. Merkel has been practicing medicine for over 34 years and is rated as an Elite expert by MediFind in the treatment of Granulomatosis with Polyangiitis. He is also highly rated in 21 other conditions, according to our data. His top areas of expertise are Granulomatosis with Polyangiitis, Vasculitis, Microscopic Polyangiitis, and Takayasu Arteritis. He is licensed to treat patients in Pennsylvania and Massachusetts. Merkel is currently accepting new patients.

Elite
Highly rated in
24
conditions

Canadian Rheumatology Association

CA 

Christian Pagnoux practices in Canada. Pagnoux is rated as an Elite expert by MediFind in the treatment of Granulomatosis with Polyangiitis. He is also highly rated in 24 other conditions, according to our data. His top areas of expertise are Granulomatosis with Polyangiitis, Vasculitis, Polyarteritis Nodosa, and Microscopic Polyangiitis.

 
 
 
 
Learn about our expert tiers
Learn more
Elite
Highly rated in
16
conditions
Rheumatology

Cleveland Clinic Health System

Cleveland Clinic Main Campus

9500 Euclid Ave, 
Cleveland, OH 

Carol Langford is a Rheumatologist in Cleveland, Ohio. Langford has been practicing medicine for over 35 years and is rated as an Elite expert by MediFind in the treatment of Granulomatosis with Polyangiitis. She is also highly rated in 16 other conditions, according to our data. Her top areas of expertise are Granulomatosis with Polyangiitis, Vasculitis, Microscopic Polyangiitis, and Temporal Arteritis. She is licensed to treat patients in Ohio. Langford is currently accepting new patients.

What are the support groups for Granulomatosis with Polyangiitis?

Support groups with others who suffer from similar diseases may help people with the condition and their families learn about the diseases and adjust to the changes associated with the treatment.

What is the outlook (prognosis) for Granulomatosis with Polyangiitis?

Without treatment, people with severe forms of this disease can die within a few months.

With treatment, the outlook for most patients is good. Most people who receive corticosteroids and other medicines that slow the immune response get much better. Most people with GPA are treated with ongoing medicines to prevent relapse for at least 12 to 24 months.

What are the possible complications of Granulomatosis with Polyangiitis?

Complications most often occur when the disease is not treated. People with GPA develop tissue damage in the lungs, airways, and the kidneys. Kidney involvement may result in blood in the urine and kidney failure. Kidney disease can quickly get worse. Kidney function may not improve even when the condition is controlled by medicines.

If untreated, kidney failure and possibly death occur in most cases.

Other complications may include:

  • Eye swelling
  • Lung failure
  • Coughing up blood
  • Nasal septum perforation (hole inside the nose)
  • Side effects from medicines used to treat the disease
When should I contact a medical professional for Granulomatosis with Polyangiitis?

Call your provider if:

  • You develop chest pain and shortness of breath.
  • You cough up blood.
  • You have blood in your urine.
  • You have other symptoms of this disorder.
How do I prevent Granulomatosis with Polyangiitis?

There is no known prevention.

Granulomatosis with polyangiitis on the leg
Respiratory system
What are the latest Granulomatosis with Polyangiitis Clinical Trials?
A Randomized, Double-blind, Active-controlled 52-week Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy
Match to trials
Find the right clinical trials for you in under a minute
Get started
The Assessment of Prednisone In Remission Trial (TAPIR) - Centers of Excellence Approach
What are the Latest Advances for Granulomatosis with Polyangiitis?
Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study.
Tired of the same old research?
Check Latest Advances
SUCCESSFUL TREATMENT FOR OTITIS MEDIA AND SINUSITIS ASSOCIATED WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS USING ANTI-IL-5 RECEPTOR MONOCLONAL ANTIBODY BENRALIZUMAB.
Who are the sources who wrote this article ?

Published Date: October 25, 2021
Published By: Diane M. Horowitz, MD, Rheumatology and Internal Medicine, Northwell Health, Great Neck, NY. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

What are the references for this article ?

Grau RG. Drug-induced vasculitis: New insights and a changing lineup of suspect. Curr Rheumatol Rep. 2015;17(12):71. PMID: 26503355 pubmed.ncbi.nlm.nih.gov/26503355/.

Pagnoux C, Guillevin L; French Vasculitis Study Group; MAINRITSAN investigators. Rituximab or azathioprine maintenance in ANCA-associated vasculitis. N Engl J Med. 2015;372(4):386-387. PMID: 25607433 pubmed.ncbi.nlm.nih.gov/25607433/.

Stone JH. The systemic vasculitides. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 254.

Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. [published correction appears in Ann Rheum Dis. 2017;76(8):1480]. Ann Rheum Dis. 2016;75(9):1583-1594. PMID: 27338776 pubmed.ncbi.nlm.nih.gov/27338776/.